Microbot Medical expands LIBERTY System adoption to Michigan
Microbot Medical Inc. announced the first adoption of its LIBERTY Endovascular Robotic System by a major health system in Michigan, expanding its presence into the Midwest U.S. This follows a similar adoption in North Carolina and signals growing demand for robotic solutions in the 2.5 million annual peripheral endovascular procedures in the U.S. The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for these procedures and recently gained approval for marketing in Israel.
*this image is generated using AI for illustrative purposes only.
Microbot Medical Inc. has secured the first adoption of its LIBERTY Endovascular Robotic System in Michigan, expanding its footprint across the Midwest U.S. region. A major health system in Michigan, recognized as one of the largest in the state, has implemented the technology, marking a significant step in the company's commercialization efforts. This development follows a recent announcement regarding the system's first healthcare system customer in North Carolina, reinforcing growing interest among health systems in advanced robotic solutions.
The company attributes this progress to increasing demand for robotic assistance in peripheral endovascular procedures and a rising readiness among major health systems to integrate such technologies into routine vascular care. Microbot Medical views these adoptions as validation of its recent transition to full market release in the U.S. The U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually, representing a substantial commercial opportunity.
Harel Gadot, Chairman, President & CEO of Microbot Medical, highlighted the strategic importance of these expansions. He stated that the addition of new healthcare system customers reflects growing recognition that robotics can be delivered in a practical and accessible manner. Gadot noted increasing interest from physicians and hospital leaders who recognize the system's potential to enhance procedural workflows and support physician well-being, positioning the company for continued growth and market penetration.
The LIBERTY System is distinguished as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation with the aim of reducing radiation exposure and physical strain on medical personnel. Recently, the system also received regulatory approval from the Israeli Ministry of Health's AMAR Division, authorizing the company to market and sell the LIBERTY System in Israel.
Key Features of the LIBERTY System
| Feature | Description |
|---|---|
| Regulatory Status | FDA-cleared for peripheral endovascular procedures |
| Design | Single-use, remotely operated robotic system |
| Primary Goal | Precise vascular navigation, reduced radiation exposure, reduced physical strain |
| Recent Approval | Approved by Israeli Ministry of Health's AMAR Division |
What are Microbot Medical's specific revenue projections following the recent regulatory approval in Israel?
How does the company plan to scale production to meet potential demand from the 2.5 million annual U.S. procedures?
Will the recent adoptions in Michigan and North Carolina lead to accelerated expansion into other U.S. regions this year?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
